In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enigma gains PCR patents:

This article was originally published in Clinica

Executive Summary

Enigma Diagnostics has gained 25 patents and patent applications from the UK's Defence Science and Technology Laboratory (Dstl) after signing an exclusive licensing deal. The patents relate to a broad range of real-time PCR technologies in development, including Pyrostart, ResonSense and Temperature Control. The PCR systems are being developed for the real-time detection and identification of infectious organisms in clinical, environmental and biological samples. Under the agreement, Porton Down, UK-based Enigma will be able to develop its own patent portfolio with any improvement that is made to the technologies. It will also enable the company to sub-license the technologies for PCR and non-PCR applications. The patents, which were previously the responsibility of Dstl, are managed by Enigma with effect from August 13. The licence agreement will remain in place until 2026.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts